scientifyRESEARCH
research funding database

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

RESEARCH FUNDING

CureSearch Acceleration Initiative International Award in Pediatric Cancer Drug Development

Share

Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange plus symbol appears between the two logos.
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

CureSearch’s Acceleration Initiative projects are highly innovative, address a significant challenge in pediatric cancer drug development, and have a strong probability of clinical application — ready to reach patients within three to five years. The 2023 AI solicitation is requesting translational and preclinical projects aiming to bring advances to lead to clinical studies that address areas of high unmet need and will lead to therapies for children within a three-year timeframe. Applicants are encouraged to describe how their proposal will address a challenge and overcome critical barriers to pediatric oncology treatment. Applications are open to researchers worldwide. Applicants may apply for up to 1.5 million USD for up to 3 years, including 10% indirect costs.

Letters of intent are due on May 26, 2023. Invited full applications are due on July 7, 2023.

Full application due:
July 7, 2023

non member

More related info for you

Register for free

Don´t have an account?

Start with our free trial to enjoy our 7 days of unlimited grant access and our premium features.

or, Choose a plan to subscribe to our premium membership.

Be the first to know

Sign-up for Personalized Grant alerts

Logo3

Sign-up for our
monthly research
funding newsletter

You can unsubscribe at any time.